secwatch.observer — SEC 8-K summary
======================================

Issuer:     Axe Compute Inc. (AGPU)
CIK:        0001446159
Form:       8-K
Filed at:   2024-05-15T23:59:59+00:00
Accession:  0001171843-24-002893
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Predictive Oncology Q1 net loss $4.2M on revenue $0.4M; cash $5.2M, EPS -$1.04
------------------------------------------------------------------------------

- Net loss of ~$4.2M, wider than $3.5M loss in Q1 2023; diluted EPS -$1.04 vs -$0.86.
- Revenue $419,646, up 75% YoY from $239,895, driven by STREAMWAY system sales.
- Cash $5.2M at March 31, 2024, down from $8.7M at Dec 31, 2023.
- Abstract accepted at ASCO 2024 for ovarian cancer machine-learning survival model; collaboration with Fujifilm on endotoxin testing announced.
- FluGen collaboration for intranasal flu vaccine under $6.2M DoD grant progressing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1446159/000117184324002893/0001171843-24-002893-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1446159/000117184324002893/f8k_051424.htm
  HTML page:      https://secwatch.observer/filing/0001171843-24-002893

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer